胃癌新辅助化疗后肿瘤退缩分级预测因素的研究进展

doi:10.3760/cma.j.cn371439-20220624-00023

摘要/Abstract

摘要：

新辅助化疗对局部进展期胃癌的整体疗效已经得到认可。然而，由于肿瘤的异质性，新辅助化疗对一部分患者无效。肿瘤退缩分级（TRG）在评估胃癌新辅助化疗疗效中具有独特的优势。但由于TRG依赖术后病理，挖掘TRG预测指标以更精准地选择适当的患者施行新辅助化疗成为当前的一个重要课题。因此，从生物标志物、免疫、炎症指标、身体成分、影像学指标等方面了解胃癌新辅助化疗后TRG预测因素的相关研究进展和当前研究面临的挑战，有助于进一步的临床研究和实践。

关键词: 胃肿瘤, 新辅助化疗, 肿瘤退缩分级, 预测因素

Abstract:

The overall efficacy of neoadjuvant chemotherapy for locally advanced gastric cancer has been recognized. However，neoadjuvant chemotherapy is ineffective in a subset of patients due to tumor heterogeneity. The tumor regression grade （TRG） has unique advantages in assessing the efficacy of neoadjuvant chemotherapy for gastric cancer. Nonetheless，since TRG is dependent on postoperative pathology，it becomes a significant topic today to mine TRG predictors to more accurately select appropriate patients for neoadjuvant chemotherapy. Therefore，to understand the relevant research progress and current research challenges of TRG predictors after neoadjuvant chemotherapy for gastric cancer from the aspects of biomarkers，immunity，inflammatory indicators，body composition，imaging indicators，etc.，is conducive to further clinical research and practice.

Key words: Stomach neoplasms, Neoadjuvant chemotherapy, Tumor regression grade, Predictive factors

范珊琳, 汪品秀, 孔飞, 周玉洁, 袁文臻. 胃癌新辅助化疗后肿瘤退缩分级预测因素的研究进展[J]. 国际肿瘤学杂志, 2023, 50(2): 112-116.

Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen. Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 112-116.

参考文献 45

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. DOI: 10.3322/caac.21590. doi: 10.3322/caac.21590
[2]	Petrillo A, Pompella L, Tirino G, et al. Perioperative treatment in resectable gastric cancer: current perspectives and future directions[J]. Cancers (Basel), 2019, 11(3): 399. DOI: 10.3390/cancers11030399. doi: 10.3390/cancers11030399
[3]	Davies AR, Gossage JA, Zylstra J, et al. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction[J]. J Clin Oncol, 2014, 32(27): 2983-2990. DOI: 10.1200/JCO.2014.55.9070. doi: 10.1200/JCO.2014.55.9070 pmid: 25071104
[4]	Martin-Romano P, Sola JJ, Diaz-Gonzalez JA, et al. Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer[J]. Br J Cancer, 2016, 115(6): 655-663. DOI: 10.1038/bjc.2016.252. doi: 10.1038/bjc.2016.252
[5]	Smyth EC, Fassan M, Cunningham D, et al. Effect of pathologic tumor response and nodal status on survival in the medical research council adjuvant gastric infusional chemotherapy trial[J]. J Clin Oncol, 2016, 34(23): 2721-2727. DOI: 10.1200/JCO.2015.65.7692. doi: 10.1200/JCO.2015.65.7692 pmid: 27298411
[6]	Fokas E, Liersch T, Fietkau R, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial[J]. J Clin Oncol, 2014, 32(15): 1554-1562. DOI: 10.1200/JCO.2013.54.3769. doi: 10.1200/JCO.2013.54.3769 pmid: 24752056
[7]	Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial[J]. Lancet, 2019, 393(10184): 1948-1957. DOI: 10.1016/S0140-6736(18)32557-1. doi: 10.1016/S0140-6736(18)32557-1
[8]	Al-Batran SE, Homann N, Pauligk C, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial[J]. JAMA Oncol, 2017, 3(9): 1237-1244. DOI: 10.1001/jamaoncol.2017.0515. doi: 10.1001/jamaoncol.2017.0515
[9]	Fuse N, Bando H, Chin K, et al. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase Ⅱ study[J]. Gastric Cancer, 2017, 20(2): 332-340. DOI: 10.1007/s10120-016-0606-4. doi: 10.1007/s10120-016-0606-4
[10]	Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial[J]. Lancet, 2012, 379(9813): 315-321. DOI: 10.1016/S0140-6736(11)61873-4. doi: 10.1016/S0140-6736(11)61873-4
[11]	Tong Y, Zhu Y, Zhao Y, et al. CA724 predicts tumor regression grade in locally advanced gastric cancer patients with neoadjuvant chemotherapy[J]. J Cancer, 2021, 12(21): 6465-6472. DOI: 10.7150/jca.60694. doi: 10.7150/jca.60694 pmid: 34659537
[12]	Hashimoto T, Kurokawa Y, Takahashi T, et al. Predictive value of MLH1 and PD-L1 expression for prognosis and response to pre-operative chemotherapy in gastric cancer[J]. Gastric Cancer, 2019, 22(4): 785-792. DOI: 10.1007/s10120-018-00918-4. doi: 10.1007/s10120-018-00918-4
[13]	Zurlo IV, Schino M, Strippoli A, et al. Predictive value of NLR, TILs (CD4⁺/CD8⁺) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer[J]. Cancer Immunol Immunother, 2022, 71(1): 45-55. DOI: 10.1007/s00262-021-02960-1. doi: 10.1007/s00262-021-02960-1
[14]	Ocana A, Nieto-Jiménez C, Pandiella A, et al. Neutrophils in cancer: prognostic role and therapeutic strategies[J]. Mol Cancer, 2017, 16(1): 137. DOI: 10.1186/s12943-017-0707-7. doi: 10.1186/s12943-017-0707-7 pmid: 28810877
[15]	杨银静, 李桂香, 唐敏. 纤维蛋白原、NLR及F-NLR评分在胃癌中的研究进展[J]. 国际肿瘤学杂志, 2021, 48(7): 433-435. DOI: 10.3760/cma.j.cn371439-20201230-00083. doi: 10.3760/cma.j.cn371439-20201230-00083
[16]	Lieto E, Auricchio A, Tirino G, et al. Naples prognostic score predicts tumor regression grade in resectable gastric cancer treated with preoperative chemotherapy[J]. Cancers (Basel), 2021, 13(18): 4676. DOI: 10.3390/cancers13184676. doi: 10.3390/cancers13184676
[17]	Sakin A, Sahin S, Sakin A, et al. The effect of obesity on response to neoadjuvant therapy in locally advanced gastric cancer[J]. Asian Pac J Cancer Prev, 2020, 21(9): 2723-2731. DOI: 10.31557/APJCP.2020.21.9.2723. doi: 10.31557/APJCP.2020.21.9.2723
[18]	Lin JX, Tang YH, Zhou WX, et al. Body composition parameters predict pathological response and outcomes in locally advanced gastric cancer after neoadjuvant treatment: a multicenter, international study[J]. Clin Nutr, 2021, 40(8): 4980-4987. DOI: 10.1016/j.clnu.2021.06.021. doi: 10.1016/j.clnu.2021.06.021
[19]	Lundsgaard Hansen M, Fallentin E, Lauridsen C, et al. Computed tomography (CT) perfusion as an early predictive marker for treatment response to neoadjuvant chemotherapy in gastroesophageal junction cancer and gastric cancer—a prospective study[J]. PLoS One, 2014, 9(5): e97605. DOI: 10.1371/journal.pone.0097605. doi: 10.1371/journal.pone.0097605
[20]	Petrioli R, Marrelli D, Roviello F, et al. Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T₃-T₄ non-metastatic gastric cancer[J]. Surg Oncol, 2020, 32: 2-7. DOI: 10.1016/j.suronc.2019.10.002. doi: S0960-7404(19)30325-1 pmid: 31670056
[21]	Li Z, Zhang D, Dai Y, et al. Computed tomography-based radiomics for prediction of neoadjuvant chemotherapy outcomes in locally advanced gastric cancer: a pilot study[J]. Chin J Cancer Res, 2018, 30(4): 406-414. DOI: 10.21147/j.issn.1000-9604.2018.04.03. doi: 10.21147/j.issn.1000-9604.2018.04.03
[22]	Fu J, Tang L, Li ZY, et al. Diffusion kurtosis imaging in the prediction of poor responses of locally advanced gastric cancer to neoadjuvant chemotherapy[J]. Eur J Radiol, 2020, 128: 108974. DOI: 10.1016/j.ejrad.2020.108974. doi: 10.1016/j.ejrad.2020.108974
[23]	Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial[J]. Lancet Oncol, 2016, 17(12): 1697-1708. DOI: 10.1016/S1470-2045(16)30531-9. doi: 10.1016/S1470-2045(16)30531-9
[24]	Satake H, Miki A, Kondo M, et al. Phase Ⅰ study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)[J]. ESMO Open, 2017, 2(1): e000130. DOI: 10.1136/esmoopen-2016-000130. doi: 10.1136/esmoopen-2016-000130
[25]	Kim GM, Jeung HC, Rha SY, et al. A randomized phase Ⅱ trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer[J]. Eur J Cancer, 2012, 48(4): 518-526. DOI: 10.1016/j.ejca.2011.12.017. doi: 10.1016/j.ejca.2011.12.017
[26]	Wang X, Li S, Xie T, et al. Early results of the randomized, multicenter, controlled evaluation of S-1 and oxaliplatin as neoadjuvant chemotherapy for Chinese advanced gastric cancer patients (RESONANCE trial)[J]. J Clin Oncol, 2020, 38(4_suppl): 280. DOI: 10.1200/JCO.2020.38.4_suppl.280. doi: 10.1200/JCO.2020.38.4_suppl.280
[27]	Ji J, Shen L, Li Z, et al. Perioperative chemotherapy of oxaliplatin combined with S-1 (SOX) versus postoperative chemotherapy of SOX or oxaliplatin with capecitabine (XELOX) in locally advanced gastric adenocarcinoma with D2 gastrectomy: a randomized phase Ⅲ trial (RESOLVE trial)[J]. Ann Oncol, 2019, 30(Supplement 5): v877. DOI: 10.1093/annonc/mdz394.033. doi: 10.1093/annonc/mdz394.033
[28]	Sah BK, Zhang B, Zhang H, et al. Neoadjuvant FLOT versus SOX phase Ⅱ randomized clinical trial for patients with locally advanced gastric cancer[J]. Nat Commun, 2020, 11(1): 6093. DOI: 10.1038/s41467-020-19965-6. doi: 10.1038/s41467-020-19965-6
[29]	Xie JW, Lu J, Xu BB, et al. Prognostic value of tumor regression grading in patients treated with neoadjuvant chemotherapy plus surgery for gastric cancer[J]. Front Oncol, 2021, 11: 587856. DOI: 10.3389/fonc.2021.587856. doi: 10.3389/fonc.2021.587856
[30]	Lombardi PM, Mazzola M, Achilli P, et al. Prognostic value of pathological tumor regression grade in locally advanced gastric cancer: new perspectives from a single-center experience[J]. J Surg Oncol, 2021, 123(4): 923-931. DOI: 10.1002/jso.26391. doi: 10.1002/jso.26391 pmid: 33497471
[31]	Xu X, Zheng G, Zhang T, et al. Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response[J]. Cancer Chemother Pharmacol, 2019, 84(3): 635-646. DOI: 10.1007/s00280-019-03893-4. doi: 10.1007/s00280-019-03893-4
[32]	Kurokawa Y, Shibata T, Sasako M, et al. Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507-A)[J]. Gastric Cancer, 2014, 17(3): 514-521. DOI: 10.1007/s10120-013-0294-2. doi: 10.1007/s10120-013-0294-2 pmid: 23999869
[33]	Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations[J]. Cancer, 1994, 73(11): 2680-2686. DOI: 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C. doi: 10.1002/1097-0142(19940601)73:11<2680::aid-cncr2820731105>3.0.co;2-c pmid: 8194005
[34]	Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer sta-ging[J]. CA Cancer J Clin, 2017, 67(2): 93-99. DOI: 10.3322/caac.21388. doi: 10.3322/caac.21388
[35]	Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition[J]. Gastric Cancer, 2011, 14(2): 101-112. DOI: 10.1007/s10120-011-0041-5. doi: 10.1007/s10120-011-0041-5 pmid: 21573743
[36]	Washington MK, Berlin J, Branton P, et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum[J]. Arch Pathol Lab Med, 2009, 133(10): 1539-1551. DOI: 10.5858/133.10.1539. doi: 10.1043/1543-2165-133.10.1539 pmid: 19792043
[37]	Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy[J]. Cancer, 2003, 98(7): 1521-1530. DOI: 10.1002/cncr.11660. doi: 10.1002/cncr.11660 pmid: 14508841
[38]	Ninomiya Y, Yanagisawa A, Kato Y, et al. Histological indications of a favorable prognosis with far-advanced gastric carcinomas after preoperative chemotherapy[J]. J Cancer Res Clin Oncol, 1999, 125(12): 699-706. DOI: 10.1007/s004320050337. doi: 10.1007/s004320050337 pmid: 10592104
[39]	Mirza A, Naveed A, Hayes S, et al. Assessment of histopathological response in gastric and gastro-oesophageal junction adenocarcinoma following neoadjuvant chemotherapy: which scoring system to use?[J]. ISRN Pathol, 2012, 2012: 519351. DOI: 10.5402/2012/519351. doi: 10.5402/2012/519351
[40]	Tsekrekos A, Vieth M, Ndegwa N, et al. Interobserver agreement of a gastric adenocarcinoma tumor regression grading system that incorporates assessment of lymph nodes[J]. Hum Pathol, 2021, 116: 94-101. DOI: 10.1016/j.humpath.2021.07.003. doi: 10.1016/j.humpath.2021.07.003 pmid: 34284051
[41]	Westerhoff M, Osecky M, Langer R. Varying practices in tumor regression grading of gastrointestinal carcinomas after neoadjuvant therapy: results of an international survey[J]. Mod Pathol, 2020, 33(4): 676-689. DOI: 10.1038/s41379-019-0393-7. doi: 10.1038/s41379-019-0393-7
[42]	Fernández-Aceñero MJ, Granja M, Sastre J, et al. Prognostic significance of tumor regression in lymph nodes after neoadjuvant therapy for rectal carcinoma[J]. Virchows Arch, 2016, 468(4): 425-430. DOI: 10.1007/s00428-015-1901-x. doi: 10.1007/s00428-015-1901-x
[43]	Becker K, Langer R, Reim D, et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases[J]. Ann Surg, 2011, 253(5): 934-939. DOI: 10.1097/SLA.0b013e318216f449. doi: 10.1097/SLA.0b013e318216f449 pmid: 21490451
[44]	Sakuyama N, Kojima M, Kawano S, et al. Area of residual tumor is a robust prognostic marker for patients with rectal cancer undergoing preoperative therapy[J]. Cancer Sci, 2018, 109(3): 871-878. DOI: 10.1111/cas.13521. doi: 10.1111/cas.13521
[45]	Nakamura K, Kuwata T, Shimoda T, et al. Determination of the optimal cutoff percentage of residual tumors to define the pathological response rate for gastric cancer treated with preoperative therapy (JCOG1004-A)[J]. Gastric Cancer, 2015, 18(3): 597-604. DOI: 10.1007/s10120-014-0401-z. doi: 10.1007/s10120-014-0401-z pmid: 24968818